ArticleBulletin of experimental biology and medicine2026
A Tissue-Engineered In Vitro Intestinal Wall Model for Assessing the Immunomodulatory Activity of the Human Gut Microbiota.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of in vitro models for screening the immunological activity of commensal bacteria in the human microbiota is a promising and highly relevant field of tissue engineering and experimental microbiology. This article describes a technology for fabricating a standardized, accessible, and easy-to-implement tissue-engineered in vitro model of the human intestinal wall. This model reproduces the physiologically relevant ratio of absorptive and mucin-producing enterocytes, while ensuring the spatial distribution and interaction of enterocytes and immune cells without the need for xenogeneic or synthetic scaffold materials. Exposure of the tissue-engineered intestinal model to E. coli O55:B5 LPS leads to the development of an inflammatory response, which was verified by changes in the expression level of the IL8 gene, encoding a key proinflammatory cytokine in dysbiosis. The developed tissue-engineered intestinal model can be used to screen for the immunomodulatory activity of commensal bacterial strains with potential organoprotective effects, as demonstrated by the example of the Opitutia bacterium KCR 482 strain.
Indexed as
Identifiers
42799977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.